Chemopreventive Activity of Naphthoquinones from Alkanna tinctoria (L.) Tausch in Human Colorectal Cancer Cells

Nguyen Huu Tung, Chong-Zhi Wang, Guang-Jian Du, Chun-Su Yuan, Takuhiro Uto, Yukihiro Shoyama

ABSTRACT
Botanically derived natural products have recently become an attractive source of new chemotherapeutic agents. To explore active anti-colorectal cancer compounds, we performed phytochemical studies on Alkanna tinctoria and isolated eight quinone compounds. Using spectroscopical and physicochemical methods including high-resolution mass spectrometry and NMR spectra, compounds 1, 2, 3, 5 and 6 were identified as alkannin, acetylalkannin, angelylalkannin, dimethylacryl alkannin and arnebifuranone, respectively. Novel compounds 4, 7, and 8 are named as 5-methoxyangenylalkannin, alkannfuranol and alkandiol, respectively, and structurally elucidated based on extensive spectroscopic evidence. The anti-proliferative effects of these eight compounds on HCT-116 and SW-480 human colorectal cancer cells were determined by the MTS method. Cell cycle and apoptosis were determined using flow cytometry. Enzymatic activities of caspases were determined by colorimetric assay, and interactions of compound 4 and caspase 9 were explored by docking analysis. Among the eight compounds, alkannin (1), angelylalkannin (3), and 5-methoxyangenylalkannin (4) showed strong anti-proliferative effects, while compound 4 showed the most potent effects. Compound 4 arrested cancer cells in the S and G2/M phases, and significantly induced cell apoptosis. The apoptotic effects of compound 4 were supported by caspase assay and docking analysis.

Key words: Alkanna tinctoria; Naphthoquinones; Alkannin derivatives; Novel compounds; Antiproliferation; Cell cycle; Apoptosis; caspase 9; Docking analysis; Colorectal cancer

INTRODUCTION
Many countries have been moving towards an aging society, especially Japan changed the construction of population quickly resulting in a rapidly increasing prevalence in lifestyle diseases, including colon cancer. Japanese patient survey by the Ministry of Health, Labour and Welfare reported 235,000 colon cancer patients in 2015, and this number is increasing year by year. It is said that the change of dietary life style from the typical Japanese food to the westernized style food induced its increase. Although the cancer chemotherapy has been widely developing recently, some natural product supplement, having wide spectra of bioactivity, however mild, are required. This is the reason why natural products having evident activities for cancers are particularly desirable in Japan. Considering such recent health circumstances in Japan, we selected saffron for preventing and increasing quality of life against cancers, and reviewed previously[1]. We have been serching a second candidate as anti-colorectal cancer active natural product, and reached to Alkanna tinctoria (L.) Tausch...
(Boraginaceae) which is widely distributed in Europe and Western Asia because a previous review informed a wide pharmacological activity of naphthoquinones like ulcers, inflammation, wounds\[2-4\]. It is interesting that a number of enantiomers of alkannin like shikonin were isolated from the same family Lithospermum erythrorhizon Siebold et Zuccarini which grows in Japan, Korea and China\[5\]. Both A. tinctoria and L. erythrorhizon have the long historical evidences which were listed in Material Medica and Shennong Ben Cao Jing as important medicines in around one century, individually. This is the reason why we select A. tinctoria as a second candidate because its constituents might be relatively safety.

In this review, we performed a systemic phytochemical isolation on A. tinctoria. Eight naphthoquinones were isolated and they were structurally elucidated including three novel components. The anti-proliferative effects of the eight compounds on human colorectal cancer cells were determined. To further explore the potential mechanisms of apoptosis, a structure-based docking model was simulated to get an inside view of ligand–receptor interaction.

RESOURCES OF NAPHTHOQUINONES

As previously indicated two species of Boraginaceae, A. tinctoria and L. erythrorhizon contain typical naphthoquinones like alkannin and shikonin, respectively which are the enantiomers each other. Since one other species, Arnebia euchroma grown in China is available in Japanese market, we surveyed components in three species in references\[5-11\]. Figure 1 indicated the distribution of components contained in three species. It becomes evident that the components having no hydroxyl or ether group on C-1’ position in a molecule in the early stage of biosynthetic pathway like deoxyalkannin, deoxyshikonin and arnebin-7 are contained in three species. However, after induction of oxygen function on C-1’ position S- and R-enantiomers were separately contained in A. tinctoria and L. erythrorhizino, respectively. On the other hand A. euchroma contains both enantiomers as shown in Figure 1. This evidence suggested that A. euchroma might be a hybrid between A. tinctoria and L. erythrorhizon also supported by morphological characterization. From this result it makes it clear that species can be selected for the isolation of individual enantiomer depends on the purpose of use.

ISOLATION OF NAPHTHOQUINONES FROM A. TINCTORIA

Alkannin (1) and naphthoquinone derivatives were concentrated in the pigment fraction of A. tinctoria, which is obtained by partition between hexan/CHCl\(_3\) and water\[12\]. There have been identified more than 15 alkannin analogs. The structures isolated were characterized by chemical and physicochemical methods, especially NMR and MS spectra. Of them, alkannin (1) and angelylalkannin (3) were major pigment components. We had succeeded to elucidate structures of more 6 naphthoquinones, acetylalkannin (2), 5-methoxyangenylalkannin (4), dimethylacryl alkannin (5)\[2,13\], amebifuranone (6)\[14\], alkanfuranol (7) and alkandiol (8) as shown in Figure 2.

Figures 1 Survey of related naphthoquinones in 3 species, Lithospermum erythrorhizon (Le), Arnebia euchroma (Ae) and Alkanna tinctoria (At).
Among them 4, 7 and 8 are novel naphthoquinones. It became evident that the stereochemistry of C-1′ of 1, 4-naphthoquinone derivatives from *A. tinctoria* like alkannin is specific as *S*-configuration which is an enantiomer of shikonin which has *R*-configuration as reported previously [5]. Compound 4, a red solid, gave a quasi-molecular ion peak at m/z 385.1653 [M + H]^+ in the high-resolution electrospray-ionization time-of-flight mass spectrometry (HRESITOFMS). The 1H- and 13C-NMR spectra of 4 exhibited proton signals of two ortho-coupled and one singlet aromatic protons and two conjugated carbonyl groups, indicating 4 belongs to 1,4-naphthoquinone derivatives like alkannin (1). In addition, signals of an aromatic methoxy (5-OCH₃) were observed. Further analyses of 1H and 13C NMR data suggested the presence of a 4-methylpent-3-en-1-ol side chain and an angenoyl group, which are similar to angenylalkannin (3) [13]. Furthermore, the overall structure of 4, especially linkage sites, was assigned by 1H-1H COSY, HMQC, and HMBC, respectively (Figure 3). Having established the structure of 4, like alkannin (1), the absolute configuration of C-1′ was assigned to be *S* using optical rotation value [13]. Consequently, the structure of alkannin (7) was unambiguously established as depicted in Figure 2.

Compound 8, a white amorphous powder, had the molecular formula C₁₆H₁₆O₃ on the basis of HRESIMS experiment. The 1H NMR spectrum of 8 showed signals of two aromatic protons [δ 6.62 (d, J = 8.8 Hz, H-5), 6.53 (d, J = 8.8 Hz, H-6)] typical of 2,3-disubstituted benzodihydroxyquinone, three conjugated olefinic protons [δ 5.99 (dd, J = 17.6, 10.4 Hz, H-11), 5.10 (dt, J = 10.4, 1.2 Hz, H-12), and 5.04 (dd, J = 5.6, 1.2 Hz, H-10)], one oxymethine proton [δ 4.97 (d, J = 6.4 Hz, H-7)], one oxymethylene proton [δ 4.36 (s, H-15)], and one methyl group [δ 0.90 (s, H-16)], respectively. The 13C NMR spectrum showed sixteen signals including six aromatic carbons of a benzodihydroxyquinone [δ 148.6 (C-1), 121.9 (C-2), 124.5 (C-3), 150.5 (C-4), 116.2 (C-5), and 113.8 (C-6)], four conjugated olefinic carbons [δ 150.0 (C-9), 107.6 (C-10), 113.0 (C-11), and 148.6 (C-12)], two oxygenated carbons [δ 87.3 (C-7) and 71.9 (C-15)]. The 1H and 13C NMR data of 8 were quiet similar with those of rhizonone, which was isolated from *L. erythrorhizon*, apart from the benzodihydroxyquinone moiety [15].

The 1H NMR spectrum of 7 showed five aromatic/olefinic signals [δ 5.36 (t, J = 6.8 Hz, H-9), 6.28 (br s, H-13), 6.40 (s, H-6), 7.23 (br s, H-15), and 7.34 (br s, H-14)], three methylene groups [δ 2.36 (q, J = 7.2 Hz, H-10), 2.48 (t, J = 7.2 Hz, H-11), and 3.29 (s, H-7)], one vinyl methyl [δ 1.62 (d, J = 1.2 Hz, H-16)], and two methoxy groups [δ 3.89 (s, 3-OCH₃) and 3.91 (s, 4-OCH₃)], respectively. The 13C NMR spectrum showed sixteen signals of a typical 3,4-dimethoxybenzodihydroxyquinone [δ 121.1 (C-1), 140.5 (C-2), 137.4 (C-3), 139.0 (C-4), 141.7 (C-5), and 109.9 (C-6)], a mono-substituted furan ring [δ 124.9 (C-12), 111.1 (C-13), 142.6 (C-14), and 138.9 (C-15)], and isoheptenyl moiety. The 1H and 13C NMR data of 7 were quiet similar with those of amebifuranone (6) apart from the 3,4-dimethoxy-benzodihydroxyquinone moiety [14]. Furthermore, the structure of 7 was confirmed by the COSY and HMBC spectra (Figure 4). Consequently, the structure of alkanfuranol (7) was unambiguously established as depicted in Figure 2.
of 8 were confirmed by COSY and HMBC experiments. As shown in Figure 5, the 1H-1H COSY experiment on 8 indicated the presence of partial structures written in bold lines; and in the HMBC spectrum, the long-range correlations were observed between the following protons and carbons: H-5 and C-1,3; H-6 and C-2,4; H-7 and C-1,3,9; H-15 and C-8,10; H-16 and C-8,12,14. Hence, the planar structure of alkandiol (8) was established as depicted in Figure 1. The absolute stereochemistry of 8 has not achieved yet although its NOESY spectrum was recorded and the cross-peaks of H-7/H-8 and H-7/H-16 were observed (Figure 5).

The occurrence of alkandiol (8) in A. tinctoria, the diol form of rhizoneone, which is a novel metabolite putatively derived from geranylhydroquinone, has further suggested the similar biosynthesis pathway between alkannin and shikonin derivatives[7,13,18].

**ANTI-PROLIFERATIVE EFFECTS OF 8 COMPOUNDS ON HUMAN COLORECTAL CANCER CELL LINES, HCT-116 AND SW-480 CELLS**

Previous reports informed that naphthoquinones had anti-cancer activity[17,18]. We evaluated the anti-proliferative effects of eight compounds using two human colorectal cancer cell lines, HCT-116 and SW-480. The eight compounds showed different anti-proliferative effects on the two cancer cell lines. At the tested concentrations (3-50 µM), compound 8 did not inhibit cancer cell growth on either of the two cancer cell lines. Compounds 1 and 4 showed strong anti-proliferative effects. At concentrations of 3 µM and 10 µM, compound 1 inhibited cell growth by 29.7% and 59.3%, while compound 4 inhibited cell growth by 43.1% and 77.4%, respectively. Compared to the other seven compounds, compound 4 showed the strongest anti-proliferative effects on HCT-116 cells. Compounds 3 and 5 showed moderate effects; when treated with 30 µM the cancer cell growth was inhibited by 77.8% and 69.6%, respectively. Regarding the effects on HCT-116 cells, Compounds 6 and 7 showed relatively weak anti-proliferative effects, and at the concentration of 50 µM, HCT-116 cell growth was inhibited by 91.7% and 92.5%, respectively. Compound 2 showed some anti-proliferative effects on SW-480 cells, but such effects were not observed in HCT-116 cells. Compound 6 showed different potential for cancer cell growth inhibition. The IC50 of compounds 1-8 on HCT-116 cells are: 7.8, >50, 16.3, 4.4, 20.4, 34.6, 39.9, >50 (µM), respectively.

Isolated compounds showed different anti-proliferative effects on SW-480 cells. However, the sensitivity of certain compounds on SW-480 cells was not similar to HCT-116 cells. Compounds 2 and 6 showed relatively weak anti-proliferative effects; compound 5 showed a moderate effect; compounds 1, 3, and 4 showed relatively strong effects, while compound 4 showed the strongest cancer cell inhibition effect on SW-480 cells. The IC50 of compounds 1–8 on SW-480 cells are 15.1, 34.1, 17.0, 9.6, 22.9, 40.0, 19.0, >50, respectively. Data from both the HCT-116 and SW-480 cell lines suggested that the strongest anti-proliferative effect was observed when using compound 4, a novel isolated compound.

**EFFECTS OF 8 COMPOUNDS ON CELL CYCLE DISTRIBUTION OF SW-480 CELLS**

To examine whether proliferation in treated cells decreased because of cell cycle arrest at a specific phase, cell cycle profiles were determined using flow cytometry after staining with PI. Besides compound 8, the other seven compounds induced cell cycle profile changes in different patterns. After treatment with 10 µM of compounds 5 and 7, the SW-480 cells were arrested mainly in the G2/M phase. Compounds 1, 2, 3, 4, and 6 decreased the percentage of cells in the G1 phase and increased cell proportions in both the S and G2/M phases. S phase cells became a major group, especially in treatment with higher concentrations. Among the 8 compounds, because compound 4 showed most potent anti-proliferative effect, and also possessed marked activity on S and G2/M phase arrest, the expressions of proteins that control S and G2/M phase transition were evaluated. Compared to the control, expression of cyclin B1 and cdc2 were decreased dose-dependently. On the other hand, compound 4 significantly up-regulated p21, while slightly increasing cdk2. Our results were consistent with the role of these proteins in the regulation of the S and G2/M transition[19,20]. Data from this study suggests that those seven compounds arrested SW-480 cells in the S and G2/M phases, and compound 4 induced S and G2/M arrest through the modulation of cell cycle-regulating proteins.

**APOPTOTIC INDUCTION EFFECTS OF 8 COMPOUNDS ON SW-480 CELLS**

Apoptosis is a highly regulated programmed cell death process in which cells undergo inducible nonnecrotic cellular suicide, and thus plays an important role in anticarcinogenesis. Apoptosis is characterized by distinct morphological changes such as cell shrinkage, chromatin condensation, plasma membrane blebbing, and oligonucleosomal DNA fragmentation[21]. To explore the potential mechanism through which the tested compounds inhibit cell growth, cell apoptosis was assayed by flow cytometry after staining with double annexin V and PI in SW-480 cells. Annexin V can be detected in both the early and late stages of apoptosis. PI enters the cell in late apoptosis or necrosis. Viable cells were negative for both annexin V and PI; early apoptotic cells were positive for annexin V and negative for PI; late apoptotic or necrotic cells displayed both positive annexin V and PI (upper right quadrant); non-viable cells which underwent necrosis were positive for PI and negative for annexin V. After treatment for 48 h, except for compounds 2, 5, 6, and 8, the other four compounds significantly induced cancer cell apoptosis at concentrations of 10 and 30 µM.

Compared to the control (5.1%), the percentages of cells in both early and late apoptosis for each compound (treatment with 10 µM and 30 µM) were: Compound 1 (47.2%, 68.0%), compound 3 (38.9%, 83.2%), compound 4 (86.4%, 88.8%), and compound 7 (60.6%, 73.9%), respectively. This result suggests that the novel compound 4 possesses the most potent apoptotic induction activity.
ACTIVITIES OF COMPOUND 4 ON CASPASES 3 AND 9

Apoptosis induction involves the activation of caspases, which can be divided into 2 groups: initiator caspases and their downstream effector caspases\[^{22}\]. Initiator caspases, such as caspase-8 and -9 are self-activated in response to apoptotic stimulations. Caspase-8 has been identified as the initiator caspase induced by death receptors, and caspase-9 has been proposed as another initiator caspase in the mitochondria-dependent apoptotic pathway. Caspase-3 is a critical effector caspase and initiates the apoptotic damage\[^{23}\]. Activation of caspase-3 requires the activation of initiator caspases, such as caspase-8 and caspase-9.

Furthermore, caspase 3 and caspase 9 are two known key proteins of the caspase family of proteases that are highly conserved in multicellular organisms and function as central regulators of apoptosis. They have been identified as playing a key role in the progression of apoptosis\[^{24-26}\]. To further characterize the potential mechanism of the anticancer effect of compound 4, we conducted caspase assays. The treatment of SW-480 cells with 5 µM of compound 4 for 24 h increased the protease activities of caspases 3 and 9 as shown in Figure 6. These activities were further increased when treated with 10 µM of compound 4. At this treatment concentration, protease activity was increased by 85.2% for caspase 3, and 125.5% for caspase 9. However, no increase of their activities was found at the treatment with 15 µM. The Western blot assay supported our results obtained by the protease activity assay.

Apoptosis is considered an important mechanism in the inhibition of cancer cells, and many cancer chemotherapeutic agents are strong apoptotic inducers against cancer cells\[^{27}\]. In this study, we assayed the effect of eight compounds on cancer cell apoptosis, and observed that the anti-proliferation of potent compounds was related to their apoptotic response on colon cancer cells. To explore apoptotic induction mechanisms, we performed a caspase assay. We observed that compound 4 upregulated the expression of caspases 3 and 9, though this compound more significantly induced expression of caspase 9. Apoptosis occurs via a complex signaling cascade that is regulated at multiple points and involves many proteins. Caspase 9 is situated at critical points in apoptotic pathways and as a result plays a central role in apoptosis signal transduction\[^{28}\]. It is known that clinical drug development is a very long process and its success rate is low. However, many available anti-cancer drugs were originated from natural products. Compound 4 could be a good chemopreventive potential with possible clinical implications since the compound inhibited human colon cancer growth although our data are only an initial step for possible chemopreventive drug development.

RECEPTOR DOCKING ANALYSIS

The possible binding modes of compound 4 at the catalytic domains of human caspase 9 were predicted using the docking program Surflex-Dock. The structure of compound 4 was generated, and the protein crystal structure of caspase 9 was obtained. For the docking analysis, the protein structure was prepared by adding hydrogen atoms and missing side chain atoms and removing water molecules. Intermolecular interaction between compound 4 and caspase 9 was analyzed, and the key pharmacophore in the ligand was identified\[^{28,29}\].

Since compound 4 significantly increased caspase 9 activity, to address if compound 4 might physically interact with caspase 9, we examined compound 4 docking for human caspase 9. The Surflex-Dock program was used to predict the binding sites of compound 4 to caspase 9. The energetically most favorable position for compound 4 interactions with caspase 9 is shown in Figure 7. With \textit{in silico} modeling, it is suggested that compound 4 forms hydrogen bonds with Asp-340 and Ser-339 at the active site of caspase 9 through its hydroxyl groups. In addition, compound 4 is predicted to show significant binding affinity for caspase 9, suggesting that compound 4 directly interacts with caspase 9.

Our docking analysis suggested the existence of an interaction site between compound 4 and caspase 9. Compound 4-induced apoptosis may occur in part through direct interactions with this protein.

---

**Figures 6** Effect of compound 4 on caspase 3 and 9.

**Figures 7** Docking analysis of compound 4 on caspase 9.
CONCLUSION

The use of herbal medicines has been on the rise in cancer patients. As an alternative adjuvant to cancer chemotherapy, herbal medicines may act by increasing the sensitivity of neoplastic cells to chemotherapy and by reducing toxic and adverse effects induced by chemotherapeutic agents, without interfering with their tumoricidal effects. It is known that botanicals have been a significant resource to several of the currently used efficacious chemotherapeutic agents. There needs to be a continued effort to tap this resource and explore botanical or herbal active components with novel, potent, and distinct anti-cancer actions.

This review is a good example to select resources contained compounds having enantiomers because the naphthoquinone derivatives from *A. tinctoria* like alkannin is specific as S-configuration which is an enantiomer of shikonin which has R-configuration. Therefore, we will be able to select species for the purpose of use.

We isolated eight compounds from *A. tinctoria*, including three novel compounds. Among the eight compounds, six are alkannin derivatives, including compound 4. The anti-proliferative activities of the eight compounds on different human colorectal cancer cell lines were determined indicating that 5-methoxyangylenylalkannin (4) showed the most potent anti-proliferative and apoptotic induction activities compared to alkannin (1) and its other derivatives. Receptor docking analysis suggests the existence of an interaction site between compound 4 and caspase 9 resulting that compound 4-induced apoptosis may occur in part through direct interactions with this protein.

CONFICT OF INTEREST

All authors declared no potential conflicts of interest.

REFERENCES

1. Tanaka T, Mori T, Yuan CS, Soeda S, Tung NH, Shoyama Y. The Function of Saffron and its Constituent in Gastroenterological Tissues. *Global J Gastroenterology Hepatology* 2015; 3: 31-38.

2. Papageorgiou VP. New pigment of Alkanna-tinctoria having naphthoquinone structure. *Planta Med* 1977; 31: 390-394.

3. Papageorgiou VP. Wound healing properties of naphthoquinone pigments from Alkanna tinctoria. *Experientia* 1978; 34: 1499-1501.

4. Papageorgiou VP, Winkler A, Sagredos AN, Digenis GA. Studies on the relationship of structure to antimicrobial properties of naphthaquinones and other constituents of Alkanna tinctoria. *Planta Med* 1979; 35: 56-60.

5. Kuroda C, Wada M. Studies on the Constitution of Shikonin. *Syntheses of Iso-hexyl-naphthaquinaz and the Related Compounds. Proc Imp Acad* 1936; 12: 239-241.

6. Morimoto I, Hirata Y. New naphthoquinone derivatefs from Lithospermum erythrorhizon. *Tetrahedron Lett* 1966; 7: 3677-3680.

7. Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D, Nicolaou KC. The chemistry and biology of alkanin, shikonin, and related naphthaquinaz natural products. *Angew Chem Int Ed* 1999; 38: 270-300.

8. Papageorgiou VP, Digenis GA. Isolation of 2 new alkannin esters from Alkanna-tinctoria. *Planta Med* 1980; 39: 81-84.

9. Assimopoulou AN, Sturm S, Stupner H, Papageorgiou VP. Preparative isolation and purification of alkannin/shikonin derivatives from natural products by high-speed counter-current chromatography. *Biomed Chromatogr* 2009; 23: 182-198.

10. Assimopoulou AN, Boskou D, Papageorgiou VP. Antioxidant activities of alkannin, shikonin and Alkanna tinctoria root extracts in oil substrates. *Food Chem* 2004; 87: 433-438.

11. Ozer MS, Sanikurcu C, Tepe B, Can S. Essential oil composition and antioxidant activities of alkane (Alkanna tinctoria subsp. tinctoria). *Food Sci Biotechnol* 2010; 19: 1177-1183.

12. Tung NH, Wang CZ, Yuan CS, Du GJ, Shoyama Y. Naphthoquinone components from Alkanna tinctoria (L.) Tausch show significant antiproliferative effects on human colorectal cancer cells. *Phytother Res* 2013; 27: 66-70.

13. Sevimli-Gur C, Akgun HI, Deliloglu-Gurhan I, Korkmaz KS, Bedir E. Cytotoxic naphthaquinones from Alkanna cappadocica (perpendicular). *J Nat Prod* 2010; 73: 860-864.

14. Yao XS, Ebizuka Y, Noguchi H, Kiuchi F, Shihuya M, Itaka Y, Seto H, Sankawa U. Biologically active constituents of Arnebia euchroma: Structures of new monoterpenylbenzoquinones: Arnebinone and arnefiburanone. *Chem Pharm Bull* 1991; 39: 2962-2964.

15. Fukui H, Feroz Hasan AFM, Kyoo M. Formation and secertion of a unique quinone by hair root cultures of Lithospermum erythrorhizon. *Phytochemistry* 1999; 51: 511-515.

16. Inouye H, Ueda S, Inoue K, Matsumura H. Biosynthesis of shikonin in callus cultures of Lithospermum erythrorhizon. *Phytochemistry* 1979; 18: 1301-1308.

17. Kapadia GJ, Balasubramanian V, Tokuda H, Konoshima T, Takasaki M, Koyama J. Anti-tumor promoting effects of naphthoquinone derivatives on short term Epstein-Barr early antigen activation assay and in mouse skin carcinogenesis. *Cancer Lett* 1997; 113: 47-53.

18. Kim JA, Lee EK, Park SJ, Kim ND, Hyun DH, Lee CG. Novel anti-cancer role of naphthazarin in human gastric cancer cells. *Int J Onco* 2012; 40: 157-162.

19. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Scelfani RA. Silibinin upregulates the expression of cycclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. *Oncogene* 2003; 22: 8271-8282.

20. Hsu JD, Kao SH, Ou TT, Chen YJ, Li YJ, Wang CJ. Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27(Kip1) attributed to disruption of p27(Kip1)/Skp2 complex. *J Agric Food Chem* 2011; 59: 1996-2003.

21. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol* 2007; 35: 495-516.

22. Degtirev A, Boyce M, Yuan J. A decade of caspases. *Oncogene* 2003; 22: 8543-67.

23. Ukekaya E, Acilan C, Yilmaz Y. Apoptosis: Why and how does it occur in biology? *Cell Biochem Funct* 2011; 29: 468-480.

24. Nicholson DW, Thornberry NA. Apoptosis. Life and death decisions. *Science* 2003; 299: 214-215.

25. Creaugh EM, Martin SJ. Caspases: cellular demolition experts. *Biochem Soc Trans* 2001; 29: 696-702.

26. D’Amelio M, Cavallucci V, Cecconi F. Neuronal caspase-3 signaling: not only cell death. *Cell Death Differ* 2010; 17: 1104-1114.

27. Sampson W. Natural products and cancer. In: Yuan CS, Bieber EJ, Bauer BA, eds. A Textbook of Complementary and Alternative Medicine, 2nd edn. London: *Parthenon/CRC*, 2006: 645-54.

28. Westle ML, Laußmann MA, Rehm M. The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. *Eur Cell Res* 2012; 318: 1213-20.

29. Giganti D, Guilemain H, Spadoni JL, Nilges M, Zagury JF, Montes M. Comparative evaluation of 3D virtual ligand screening methods: impact of the molecular alignment on enrichment. *J Chem Inf Model* 2010; 50: 992-1004.

30. Okaku O, White JD. Herbal therapy use by cancer patients: a literature review on case reports. *Eur J Cancer* 2011; 47: 508-14.

31. Wang CZ, He H, Wang X, Yuan CS. Trends in scientific publications of chinese medicine. *Am J Chin Med* 2012; 40: 1099-1108.
32 Wang HY, Qi LW, Wang CZ, Li P. Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides. *Am J Chin Med* 2011; 39: 1103-15.
33 Wang CZ, Calway T, Yuan CS. Herbal medicines as adjuvants for cancer therapeutics. *Am J Chin Med* 2012; 40: 657-669.
34 Mann J. Natural products in cancer chemotherapy: past, present and future. *Nat Rev Cancer* 2002; 2: 143-148.
35 Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. *Life Sci* 2005; 78: 431-441.
36 Ernst E. The role of complementary and alternative medicine in cancer. *Lancet Oncol* 2000; 1: 176-180.

**Peer reviewer:** Lizong Shen, Associate Professor, Division of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, China.